Idexx Laboratories, Inc.


Market Cap$39.68B

Compare Idexx Laboratories

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Idexx Laboratories, Inc.Idexx Laboratories, Inc.470%57%10.90.6
marketMarket Avg59.71.27%30%-0.9
HealthcareHealthcare Avg64.51.29%15%7.10.8

Earnings Call Q4 2023

February 5, 2024 - AI Summary

IDEXX Laboratories reported strong fourth quarter and full year 2023 results, with revenues increasing by 8% organically in Q4 and 9% for the full year.
CAG Diagnostic recurring revenue grew by 10% organically in Q4, driven by gains in both the US (9%) and international regions (12%).
The company achieved solid organic growth across major testing modalities, with VetLab consumable revenues increasing by 13% organically in Q4.

Exclusive for Stockcircle Pro members

Sign upSign Up

Current Fair Value

66.8% downside

Overvalued by 66.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$39.68 Billion
Enterprise Value$40.18 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$10.06
Outstanding Shares83,054,119
Avg 30 Day Volume400,200


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio46.96
Price to Sales10.86
Price to Book Ratio28.11
Enterprise Value to Revenue10.97
Enterprise Value to EBIT36.62
Enterprise Value to Net Income47
Total Debt to Enterprise0.02
Debt to Equity0.64

Revenue Sources

No data

ESG Score

No data

About Idexx Laboratories, Inc.

CEO: Jonathan Jay Mazelsky